235P - Do FGFR2 and 3 proteins have a role in the prognosis of urothelial bladder carcinoma?

Background

Erdafitinib is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor recently approved for treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has susceptible FGFR3 or FGFR2 genetic alterations and has progressed during or following at least one line of prior platinum-containing chemotherapy. Since FGFR genomic alterations have become a cornerstone in UC, we aimed to assess the prognostic role of the IHC expression of FGFR2 and FGFR3 in UC patients.

Methods

This retrospective study included cases of invasive urothelial carcinoma either pure or with squamous differentiation. All biopsies were stained for FGFR2 and FGFR3 antibodies. Complete clinical and survival data were collected and analyzed.

Results

This study included sixty patients with urothelial carcinoma. FGFR2 positivity is significantly associated with high grade and advanced stage (P= 0.044, and 0.048 respectively). Also, median FGFR2 IRS was higher in high grade cases (P= 0.027). Moreover, cases presented with PNI showed a higher median percentage of FGFR2 (P= 0.023). Furthermore, There is significant indirect linear correlation between FGFR3 percent of expression and number of positive lymph nodes (r= -0.265, P=0.041). After median follow up duration of 39 months, forty-four patient had available data for survival analysis, the mean OS and PFS were 47.4 (95% CI= 39.4-55.5) and 47.3 (95%CI= 38.7-56) months, respectively. The univariate analysis for OS revealed that presence of anemia at presentation, advanced TNM stage, and presence of distant metastasis are associated with shorter OS time ( P = 0.011, 0.007, and 0.002, respectively. Regarding PFS, the univariate analysis showed the presence of hydronephrosis at presentation is associated with shorter PFS ( P =0.029). Moreover, as with OS, presence of anemia at presentation, advanced TNM stage, and distant metastasis negatively affect PFS ( P = 0.035, 0.014, and 0.004, respectively. Regarding FGFR2 & 3 immunostaining no significant effect on neither OS nor PFS.

Conclusions

High FGFR2 expression may be associated with poor prognostic parameters, while high FGFR3 expression may be associated with good prognostic parameters.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Menoufeya University.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.